make it happen at the moment. The percentage of Black Americans who take part in clinical trials is three percent.
In addition, socioeconomic determinants of health, including poverty, lack of access to treatment, and racism in medicine, are often held responsible for the unequal results of breast cancer.
RELATED: A New Immunotherapy Medicine Can Help Black Women Combat Triple-Negative Breast Cancer
Treatment Efficiency
After completing therapy, Black women still have a 39 percent greater recurrence risk than white women. Black female survivors had a relative risk of mortality 71 percent greater than white female survivors.
Standard-of-care medications have been shown to be effective in clinical studies, and here’s the kicker: Instead of testing them on Black people, they were used on white women. So, it couldn’t be more obvious, that we don’t respond to the medications how they expect. Drugs aren’t being appropriately tested if only given to white women since our bodies aren’t used as controls.
When a medicine finally comes out that says, “This drug is particularly for Black breast cancer, for Black women,” that will be a beautiful day. Improving scientific knowledge is the only path to making it a reality, and it’s one that must be prioritized. Despite the fact that not everyone requires the same kind of screening, what goes on throughout the screening process is also overlooked.
Increasingly, we hear, “We’re getting better.” In fact, death rates are indeed decreasing. Treatment for breast cancer is improving, but it is worrying that Black women are not benefiting from these advancements at the same pace as other women.